Jasper Ridge Partners, L.P. Arcellx, Inc. Transaction History
Jasper Ridge Partners, L.P.
- $3.1 Billion
- Q1 2025
A detailed history of Jasper Ridge Partners, L.P. transactions in Arcellx, Inc. stock. As of the latest transaction made, Jasper Ridge Partners, L.P. holds 11,820 shares of ACLX stock, worth $842,884. This represents 0.02% of its overall portfolio holdings.
Number of Shares
11,820
Previous 11,820
-0.0%
Holding current value
$842,884
Previous $900,000
13.89%
% of portfolio
0.02%
Previous 0.03%
Shares
2 transactions
Others Institutions Holding ACLX
# of Institutions
211Shares Held
48.7MCall Options Held
764KPut Options Held
296K-
Paradigm Biocapital Advisors LP New York, NY4.49MShares$320 Million15.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.99MShares$284 Million0.0% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$267 Million23.3% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$251 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.04MShares$217 Million4.14% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $3.12B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...